Platelet-activating Factor and Its Receptor Mediate Melanoma Progression by Regulating Expression of MMP-2, MT1-MMP and MCAM/MUC18

Vladislava O. Melnikova,Alexandra Zeidan,Maya Zigler,Hua Wang,Dina Lev,Menashe Bar‐Eli

IF: 11.2

2007-01-01

Cancer Research

Abstract:2461 Enzymatic and oxidative degradation of cellular and lipoprotein-associated phosphatidylcholine produces key initial components of an inflammatory response - platelet-activating factor (PAF) and PAF mimetics. These short-lived biologically active phospholipid autocoids act through the specific GPCR-type PAF receptor to activate platelets, inflammatory and endothelial cells. Nevertheless, the functions of PAF/PAFR in tumor cells are largely unknown. We have found that PAF receptor antagonist PCA4248 inhibits growth of experimental A375SM human melanoma lung metastasis in nude mice. In vitro analysis of a panel of melanoma cells demonstrated that all melanoma cell lines express PAF receptor and that stimulation of metastatic melanoma cells with exogenous PAF results in the expression and activation of matrix metalloproteinases MMP-2 and MT1-MMP. This effect was mediated by PAF-induced phosphorylation and activation of transcription factors CREB and ATF-1, which occurred through a PAFR-mediated mechanism that utilized Gα q proteins, adenylate cyclase, p38 MAP kinase and protein kinase A. These results suggest that CREB and ATF-1 may act as molecular sensors to PAF-mediated stimulation. Consequently, the inflammatory tumor microenvironment may control specific transcriptional responses associated with overexpression of CREB and ATF-1, which is known to take place during the acquisition of the metastatic phenotype by melanoma cells. Our further studies indicate that PAF is also involved in constitutive gene expression in melanoma cells. First, we found that several structurally independent PAFR antagonists inhibit the in vitro growth of A375SM melanoma cells, most probably by downregulating their constitutive Cyclin D1 expression. Targeting PAFR expression in A375SM cells with small interfering RNA oligonucleotides confirmed that downregulation of Cyclin D1 expression was mediated via PAFR signaling. Second, PAFR knockdown with siRNA revealed that PAFR mediates constitutive expression of the melanoma cell adhesion protein MCAM/MUC18, a marker of metastatic melanoma as well as melanoma cancer stem cells. Conversely, inhibition of MCAM/MUC18 expression in A375SM cells by means of siRNA or shRNA led to an increase in PAFR expression, suggesting the existence of a feedback loop regulation between PAFR and MCAM/MUC18 expression. Overall, our results demonstrate that PAF acts as a promoter of melanoma metastasis by mediating gene expression in melanoma cells.